Cost regulators for NHS treatments in England and Wales have now recommended funding for Roche’s Gazyvaro for some patients with untreated follicular lymphoma, after the submission of new data by the company.
Tesaro has been asked by NICE to submit a proposal for Zejula use on the National Health Service via the Cancer Drugs Fund for maintenance treatment of patients with relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer.
It is now looking very unlikely that patients with liver cancer will get access to Bayer’s Stivarga on the NHS, after cost regulators issued final draft guidelines rejecting funding for the drug in this setting.
ViiV Healthcare, an HIV specialist firm majority owned by GlaxoSmithKline, has announced the launch of a late-stage study investigating the effectiveness of a two-drug regimen programme in patients with HIV.
Theravance Biopharma Ireland has signed a global co-development and commercialisation deal with Janssen Biotech focusing on new treatments for inflammatory intestinal conditions, including ulcerative colitis and Crohn’s disease.
Scotland’s TC Biopharm (TCB) has secured a major investment from Japan with a deal centered on developing a novel gamma-delta CAR-T therapy to treat cancer, as well as a grant from Scottish Enterprise worth £2.7 million to fund preclinical activities.